As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp…

Laurent Massuyeau introduces Swiss biosimilar commercialisation specialist iQone healthcare, why it made sense to base the company in Switzerland, its…

Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM) since August 2020, outlines his key agenda priorities as head of the…

Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different…

CCO Anil Okay introduces how Alvotech’s focus on biosimilars, comprehensive platform, differentiated portfolio approach, and commercial strategy…

Sandoz Switzerland’s Jan Tangermann highlights the importance of the Swiss affiliate to the global group and how it was able to provide sustainable…

As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM)…

Alper Ureten, Amgen VP and General Manager, sits down with PharmaBoardroom to set out his ambitions and objectives for its Biosimilars Business Unit.…

Carol Lynch, president of Sandoz US and head of Sandoz North America, recently spoke exclusively to PharmaBoardroom about how her diverse global…

Carol Lynch of Sandoz US talks candidly on the US generics market from an international perspective, market access, biosimilars uptake, talent…

In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at…

Vincent Verschraegen, country manager of Mylan Belgium and Luxembourg, speaks about his onboarding in the company and what attracted him to join the…